Clovis Oncology, Inc.
(NASDAQ : CLVS)

( )
CLVS After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. -2.82%72.010.0%$2372.81m
NVAXNovavax, Inc. 4.83%178.51251.8%$1337.92m
SRNESorrento Therapeutics, Inc. 30.51%18.821.5%$899.58m
GILDGilead Sciences, Inc. -1.21%68.511.0%$564.29m
AMGNAmgen, Inc. -1.05%238.171.3%$477.09m
REGNRegeneron Pharmaceuticals, Inc. -1.93%608.242.7%$403.31m
BNTXBioNTech SE -3.96%73.950.0%$397.67m
VRTXVertex Pharmaceuticals, Inc. -1.56%268.731.9%$369.46m
BIIBBiogen, Inc. -1.78%300.261.6%$363.67m
ILMNIllumina, Inc. -0.65%353.353.5%$342.14m
VXRTVaxart, Inc. 2.23%9.400.0%$296.32m
EBSEmergent BioSolutions, Inc. -0.19%130.416.4%$188.70m
ALXNAlexion Pharmaceuticals, Inc. -1.36%101.882.0%$166.53m
IBIOiBio, Inc. -3.16%3.680.2%$166.50m
SGENSeattle Genetics, Inc. -1.71%157.706.2%$160.68m

Company Profile

Clovis Oncology, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of cancer treatments. Its marketed product Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase (PARP), is offered for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer. The company was founded by Andrew R. Allen, Gillian C. Ivers-Read, Patrick J. Mahaffy, and Erle T. Mast on April 20, 2009 and is headquartered in Boulder, CO.